Arithmos builds a portfolio from one sentence. Make your own version of this one, or start from scratch.
Top 20 US Pharmaceutical Companies, Revenue-Weighted
By Ricky Made 29 Apr 202620 companies
Key numbers
For the time range selected above.
- vs the S&P 500
- Average per year
- Biggest drop
- Ups and downs
About this portfolio
top 20 pharmaceutical companies in the US based on revenue
- How much of each
- Bigger companies get a bigger share
- Most in one company
- 10%
- Refreshed
- Every 3 months, next 29 Jul 2026
What’s inside
20 companies. The biggest is Eli Lilly and Company at 22%. No company can be more than 10%.
Percentages are target weights at the last rebalance.
Weighting: market_capLimit per company: 10%Rebalance: quarterly
Company pages
Each company’s price history, and the other portfolios that hold it.
- Eli Lilly and Company
- Johnson & Johnson
- AbbVie Inc.
- Merck & Company, Inc.
- Amgen Inc.
- Gilead Sciences, Inc.
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Vertex Pharmaceuticals Incorporated
- Regeneron Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc.
- Teva Pharmaceutical Industries Limited
- Insmed Incorporated
- Biogen Inc.
- BioNTech SE
- United Therapeutics Corporation
- Incyte Corporation
- Viatris Inc.
- Neurocrine Biosciences, Inc.
- Jazz Pharmaceuticals plc
Theme: Healthcare and biotech stocks
Guide: How to invest in healthcare
More detail
Everything else we know about this portfolio. Open any section to dig in.Pro view: every section is open. Switch to Simple at the top of the page to tidy them away.
Risk-adjusted returns for each company, what drove the results, and how the AI built this portfolio are in Pro view.
The Sharpe ratio for each company, a suggested re-weighting and what drove the returns come with the Pro plan.
See ProAbout Top 20 US Pharmaceutical Companies, Revenue-Weighted
What stocks are in Top 20 US Pharmaceutical Companies, Revenue-Weighted?
It holds 20 companies. The largest are Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), Merck & Company, Inc. (MRK) and Amgen Inc. (AMGN), followed by GILD, PFE, BMY, VRTX and REGN. Most of the money is in healthcare.
How has Top 20 US Pharmaceutical Companies, Revenue-Weighted performed?
+38.3% since it was made, +42.8% over the past year against +14.4% for the S&P 500, +194.5% over five years in the backtest. Results before the creation date are simulated from real past prices and leave out fees and taxes. Past performance is not a guide to the future.
How is Top 20 US Pharmaceutical Companies, Revenue-Weighted weighted?
Bigger companies get a bigger share, in line with their market value. No company can be more than 10% of the portfolio. The biggest holding is Eli Lilly and Company (LLY) at 21.9%.
Can I invest in Top 20 US Pharmaceutical Companies, Revenue-Weighted?
It is not a fund you can buy. It is a list of shares you can buy yourself at your broker, and Arithmos shows you how for more than 40 brokers, or creates it as a Trading 212 pie. Arithmos is a research tool, not investment advice.
Similar portfolios
- Recession-Resilient US Defensive 20, Equal-Weighted6 of the same companies, 20 in total
- Defensive Quality 15, No Data-Centre, No Oil (Healthcare/Staples/Financials)5 of the same companies, 15 in total
- Recession-Resilient US Defensive 20, Equal-Weighted5 of the same companies, 20 in total
- Longevity & Healthspan Index4 of the same companies, 12 in total
- Defensive US Core 204 of the same companies, 14 in total
- AI Bubble Burst Defensive Index, Low-Beta Staples, Healthcare, Energy & Value Tilt3 of the same companies, 12 in total
Discussion
Results before a portfolio’s creation date are simulated from real historical prices and don’t include fees, taxes or trading costs. How we calculate performance. Nothing here is investment advice.
